Last reviewed · How we verify

Chlorofluorocarbon beclomethasone dipropionate

Research in Real-Life Ltd · Phase 2 active Small molecule

Beclomethasone dipropionate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in the lungs.

Beclomethasone dipropionate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in the lungs. Used for Asthma (maintenance and reliever therapy), Chronic obstructive pulmonary disease (COPD).

At a glance

Generic nameChlorofluorocarbon beclomethasone dipropionate
SponsorResearch in Real-Life Ltd
Drug classInhaled corticosteroid
TargetGlucocorticoid receptor
ModalitySmall molecule
Therapeutic areaRespiratory / Pulmonology
PhasePhase 2

Mechanism of action

Beclomethasone dipropionate is a synthetic corticosteroid that acts as a glucocorticoid receptor agonist. When inhaled, it reduces airway inflammation, decreases mucus production, and suppresses immune cell activation in the respiratory tract. The chlorofluorocarbon formulation serves as a propellant for delivery via metered-dose inhaler.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: